Short-Course Radiotherapy + Surgery for Soft Tissue Sarcoma
Trial Summary
What is the purpose of this trial?
The trial will use neoadjuvant hypofractionated radiotherapy followed by surgical resection in the treatment for soft tissue sarcoma. It will allow patients to be treated over a shorter course (5 or 15 days of radiation) compared to the traditional 5 week regimen. It is proposed that this will be possible without increasing the risk of wound complication or local recurrence compared with a traditional 5 week course of pre-operative radiation.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Short-Course Radiotherapy + Surgery for Soft Tissue Sarcoma?
Is short-course radiotherapy safe for soft tissue sarcoma patients?
Research shows that using short-course radiotherapy (hypofractionated radiotherapy) before surgery for soft tissue sarcoma is generally safe and does not increase the risk of side effects compared to traditional longer courses. It may also improve treatment adherence and be more cost-effective, especially for older or frail patients.12456
How is the treatment of hypofractionated radiotherapy for soft tissue sarcoma different from other treatments?
Hypofractionated radiotherapy for soft tissue sarcoma is unique because it delivers higher doses of radiation in fewer sessions, typically over a shorter period, compared to the conventional approach that spreads out smaller doses over several weeks. This can be particularly beneficial for older or frail patients who may struggle with longer treatment schedules, and it may improve treatment adherence and cost-effectiveness without increasing side effects.12456
Research Team
Eric Shinohara, MD
Principal Investigator
Vanderbilt Medical Center
Eligibility Criteria
This trial is for individuals with a confirmed diagnosis of soft tissue sarcoma located in the limbs, pelvis, chest wall or non-retroperitoneal abdominal wall. Participants should be able to perform daily activities (ECOG status 0-2) and must be fit for radiation treatment and surgery. It's not open to those who've had prior radiation in the same area, have metastatic disease, are pregnant, will receive neoadjuvant chemotherapy, or have certain diseases that increase radiation side effects.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants undergo neoadjuvant hypofractionated radiotherapy (HRT) for either 5 or 15 fractions
Surgery
Participants undergo surgical resection following completion of radiotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Hypofractionated Radiotherapy
Hypofractionated Radiotherapy is already approved in United States, European Union, Canada for the following indications:
- Soft tissue sarcoma
- Soft tissue sarcoma
- Soft tissue sarcoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanderbilt-Ingram Cancer Center
Lead Sponsor